Mortalin overexpression promotes HSC maintenance by decreasing ROS production. (A) Representative FACS profiles (upper) and population analyses (lower) of LSK cells (left) and CD150⁺ LSK cells (center), and the fluorescence intensity of DCF-DA in CD150⁺ LSK cells (right) after 10 days of culture. Sorted mortalin-overexpressing, retrovirus-transduced Kusabira-Orange⁺ LSK cells were used in these experiments. Data represent the mean ± SD (n = 7/group; *P < .05, ***P < .001). (B) PB chimerism of donor-derived cells analyzed at each month posttransplantation. Data represent the mean ± SD (n = 5/group; **P < .01, ***P < .001). BMT, bone marrow transplantation. (C) Absolute numbers of donor-derived MNCs (left) and CD34⁻ LSK cells (right) in the BM at 4 months posttransplantation. Data represent the mean ± SD (n = 5/group; **P < .01, ***P < .001). (D) Percentage of donor-derived B220⁺ B cells, CD3⁺ T cells, and Mac-1⁺/Gr-1⁺ myeloid cells in the recipient BM. Data represent the mean ± SD (n = 5/group; ***P < .001). (E) Intensity of DCF-DA fluorescence and the percentage of DCF-DA^low donor-derived LSK cells at 4 months posttransplantation. Data represent the mean ± SD (n = 5/group; **P < .01).